Biocon Biologics wraps up $3.3bn acquisition of Viatris biosimilars unit
Biocon said that its subsidiary Biocon Biologics has wrapped up the previously announced $3.3 billion acquisition of the biosimilars business of US-based pharma company Viatris. The deal, which was announced in February 2022, closed after Biocon Biologics and Viatris secured all the required approvals from major global regulators such as the US Federal Trade Commission […]